| abstract |
The present invention provides a compound having the structure of formula (I): wherein R1 is hydrogen, (C1-C6) alkyl, unconjugated (C3-C6) alkenyl, benzyl, YC(=O)(C1-C6) alkyl or -CH2CH2-O-(C1-C4) alkyl; X is CH2 or CH2CH2; Y is (C2-C6) alkylene; Z is (CH2)m, CF2, or C(=O), where m is 0, 1 or 2; R2 and R3 are selected independently from hydrogen, halogen, - (C1-C6) alkyl optionally substituted with from 1 to 7 halogen atoms, and -O(C1-C6) alkyl optionally substituted with from 1 to 7 halogen atoms, or R2 and R3 each together with the atom to which it is connected independently form C(=O), S→O, S(=O)2, or N→O; and Het is a 5- to 7- membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups. The compounds can be used to treat disease states mediated by neuronal nicotinic acetylcholine specific receptor sites. |